Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CPA3 | P15088 | 3/20 | 0.70 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.66 |
| ▸ | CPA1 | P15085 | 5/20 | 0.63 |
| ▸ | CPB1 | P15086 | 1/20 | 0.63 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.63 |
| ▸ | LAP3 | P28838 | 3/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.60 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.60 |
| ▸ | ANPEP | P15144 | 1/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12494233 | 0.90 | CYP1A2 (0.83) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL1857365 | 0.90 | CYP1A2 (0.61) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL19821208 | 0.90 | CYP1A2 (0.83) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL6724759 | 0.90 | CYP1A2 (0.83) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL10521966 | 0.89 | FOLH1 (0.72) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL10769990 | 0.89 | FOLH1 (0.72) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL7439191 | 0.88 | GRIK1 (0.64) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| Water SCHEMBL4010621 | 0.88 | CYP1A2 (0.59) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| Hydrochloric Acid SCHEMBL6717346 | 0.88 | CYP1A2 (0.79) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL7439193 | 0.88 | GRIK1 (0.64) | CYP1A2CPA3FOLH1CPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | claimed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | claimed |
| EP-0385534-B1 | Microcapsules containing hydrophobic liquid core | PROCTER & GAMBLE (US) | 1994-04-13 | — | — | EP | claimed |
| EP-3440051-B1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RES TRIANGLE INST (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-109153635-B | Neuropeptide S receptor (NPSR) agonists | 研究三角协会 | 2022-04-08 | — | — | CN | disclosed |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2021-10-12 | — | — | US | disclosed |
| US-20190092809-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| US-20190092809-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| EP-3440051-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | Research Triangle Institute (US) | 2019-02-13 | — | — | EP | disclosed |
| CN-109153635-A | Neuropeptide S receptor (NPSR) agonist | 研究三角协会 | 2019-01-04 | — | — | CN | disclosed |
| US-9950993-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-24 | — | — | US | disclosed |
| WO-2017176461-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176461-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20160271081-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271081-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271081-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092809-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NPSR1, GRPR, NPBWR1 | CYP1A2 4100/4885CPA3 1251/4885FOLH1 1267/4885 |
| US-20160271081-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | CYP1A2 694/4885CPA3 3771/4885FOLH1 1248/4885 |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | CYP1A2 4100/4885CPA3 1251/4885FOLH1 1267/4885 |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | CYP1A2 158/4885CPA3 3987/4885FOLH1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.